KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study

Ronan T. Swords, Peter L. Greenberg, Andrew H. Wei, Simon Durrant, Anjali S. Advani, Mark S. Hertzberg, Ian D. Lewis, Gabriel Rivera, Dita Gratzinger, Alice C. Fan, Dean W. Felsher, Jorge E. Cortes, Justin M. Watts, Geoff T. Yarranton, Jackie M. Walling, Jeffrey E. Lancet

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Fingerprint

Dive into the research topics of 'KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study'. Together they form a unique fingerprint.

Medicine & Life Sciences